HIV Envelope Protein gp160
"HIV Envelope Protein gp160" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An envelope protein of the human immunodeficiency virus that is encoded by the HIV env gene. It has a molecular weight of 160,000 kDa and contains numerous glycosylation sites. It serves as a precursor for both the HIV ENVELOPE PROTEIN GP120 and the HIV ENVELOPE PROTEIN GP41.
| Descriptor ID |
D019302
|
| MeSH Number(s) |
D12.776.964.775.325.164.374 D12.776.964.775.562.500.750 D12.776.964.970.880.325.164.374
|
| Concept/Terms |
HIV Envelope Protein gp160- HIV Envelope Protein gp160
- Envelope Glycoprotein gp160, HIV
- HTLV-III gp160
- HTLV III gp160
- gp160, HTLV-III
- gp160(HIV)
- HIV Envelope Glycoprotein gp160
- env Protein gp160, HIV
- gp160 Envelope Glycoprotein, HIV
|
Below are MeSH descriptors whose meaning is more general than "HIV Envelope Protein gp160".
Below are MeSH descriptors whose meaning is more specific than "HIV Envelope Protein gp160".
This graph shows the total number of publications written about "HIV Envelope Protein gp160" by people in this website by year, and whether "HIV Envelope Protein gp160" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 1 | 0 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 0 | 2 | 2 |
| 2017 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "HIV Envelope Protein gp160" by people in Profiles.
-
Ahn KW, Root MJ. Complex interplay of kinetic factors governs the synergistic properties of HIV-1 entry inhibitors. J Biol Chem. 2017 10 06; 292(40):16498-16510.
-
Cordelier P, Strayer DS. Mechanisms of alpha1-antitrypsin inhibition of cellular serine proteases and HIV-1 protease that are essential for HIV-1 morphogenesis. Biochim Biophys Acta. 2003 Jul 30; 1638(3):197-207.
-
Cordelier P, Zern MA, Strayer DS. HIV-1 proprotein processing as a target for gene therapy. Gene Ther. 2003 Mar; 10(6):467-77.
-
Foley HD, Otero M, Orenstein JM, Pomerantz RJ, Schnell MJ. Rhabdovirus-based vectors with human immunodeficiency virus type 1 (HIV-1) envelopes display HIV-1-like tropism and target human dendritic cells. J Virol. 2002 Jan; 76(1):19-31.
-
McGettigan JP, Foley HD, Belyakov IM, Berzofsky JA, Pomerantz RJ, Schnell MJ. Rabies virus-based vectors expressing human immunodeficiency virus type 1 (HIV-1) envelope protein induce a strong, cross-reactive cytotoxic T-lymphocyte response against envelope proteins from different HIV-1 isolates. J Virol. 2001 May; 75(9):4430-4.
-
Schnell MJ, Foley HD, Siler CA, McGettigan JP, Dietzschold B, Pomerantz RJ. Recombinant rabies virus as potential live-viral vaccines for HIV-1. Proc Natl Acad Sci U S A. 2000 Mar 28; 97(7):3544-9.
-
Johnson JE, Schnell MJ, Buonocore L, Rose JK. Specific targeting to CD4+ cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus envelope proteins. J Virol. 1997 Jul; 71(7):5060-8.
-
Cook DG, Turner RS, Kolson DL, Lee VM, Doms RW. Vaccinia virus serves as an efficient vector for expressing heterologous proteins in human NTera 2 neurons. J Comp Neurol. 1996 Oct 28; 374(4):481-92.